INTRODUCTION
Human multidrug resistance protein 1 (MRP1) 1 , a 1531 amino acid integral membrane phosphoglycoprotein, was originally cloned from the doxorubicin-selected multidrug resistant human small cell lung cancer cell line, H69AR (1) . Subsequent to its cloning, expression of MRP1 protein and/or mRNA has been detected in a wide range of solid and hematological tumors (2) (3) (4) (5) (6) (7) . In some cases, MRP1 expression has been shown to correlate with clinical outcome (3, 5, (7) (8) (9) . In vitro, MRP1 is able to confer resistance to many commonly used, structurally diverse natural product chemotherapeutic agents, including anthracyclines, epipodophyllotoxins, and Vinca alkaloids (10) (11) (12) (13) (14) .
In addition to conferring drug resistance, transport studies using inside-out membrane vesicles prepared from MRP1-transfected cells have shown that MRP1 is capable of transporting glutathione-, glucuronate-and sulfate-conjugated organic anions such as the cysteinyl leukotriene 4 (LTC 4 ), 17β-estradiol 17-(β-D-glucuronide) (E 2 17βG), and estrone-3-sulfate (15) (16) (17) (18) (19) (20) (21) (22) (23) . MRP1-mediated LTC 4 and E 2 17βG transport has further been demonstrated in reconstituted proteoliposomes with immunoaffinity purified native MRP1, clearly proving that MRP1 alone is sufficient for transport of conjugated organic anions (24) . LTC 4 is a high-affinity endogenous glutathione S-conjugate substrate for MRP1 and plays important roles in the inflammatory response (15, 16, 19) . In mMRP1 MRP1, or ABCC1, is a member of the ABCC branch of the ATP Binding Cassette (ABC) superfamily. This branch also includes MRP2 to -6 (ABCC2 to -6), MRP7 to -9 (ABCC10 to -12), as well as the sulphonylurea receptors SUR1 (ABCC8) and SUR2 (ABCC9), and the cystic fibrosis transmembrane conductance regulator (CFTR/ABCC7) (27) (28) (29) (30) (31) . The predicted topologies of MRP1 to -9 all contain a typical ABC transporter core region, composed of two hydrophobic membrane-spanning domains (MSDs), each with six transmembrane (TM) α-helices, and two hydrophilic nucleotide-binding domains (NBDs). In addition, MRP1, -2, -3, -6 and -7 have a third, NH 2 -terminal MSD (MSD1), that consists of five TMs with an extracellular NH 2 -terminus ( Fig. 1) (27, (31) (32) (33) (34) (35) (36) .
Previously, we have shown that a negatively charged residue, Glu
1089
, within predicted TM14 is crucial for MRP1-mediated drug resistance, particularly with respect to the anthracyclines (37) . We have also demonstrated that a number of polar amino acid residues in predicted TM17 of MRP1 are essential for MRP1 to confer drug resistance and/or to transport E 2 17βG efficiently (38) (39) (40) . In addition, these studies provided evidence for crosstalk between residues in the two TM helices (39) . TM17 of MRP1 is topologically equivalent to TM12 of Pgp which has been shown to be intimately involved in substrate binding and determination of substrate specificity (41) . Similarly, TM 14 corresponds to TM 9 of P-gp but the involvement of residues in this helix in determining substrate specificity or overall activity have only recently been identified (42, 43) .
In addition to Glu 1089 , TM14 of MRP1 contains two charged residues, Asp 1084 and Lys
1092
, as well as four amino acid residues with polar side chains (Fig. 1) . We have now characterized the role of all of these residues in determining the substrate specificity and/or overall activity of MRP1. These studies demonstrate that Lys 1092 on the same face of the helix, are important for defining the substrate specificity of MRP1 and that Asp 1084 is critical for its overall activity. We also show that proteins in which Asp 1084 has been mutated to non-carboxylic amino acids retain the ability to bind LTC 4 with high affinity but are unable to shift into a low affinity binding state in the presence of ATP and vanadate. Finally, we demonstrate that the inability of the Asp 1084 mutant protein to enter a transition state is attributable to a defect in the ability of NBD2 to hydrolyse ATP, as evidenced by a loss of vanadate dependent trapping of ADP at this NBD.
EXPERIMENTAL PROCEDURES
Materials-Culture medium and fetal bovine serum were obtained from Life Technologies, Inc. Site-directed Mutagenesis-All mutations were generated using the Transformer TM SiteDirected Mutagenesis kit (CLONTECH, Palo Alto, CA). Templates were prepared as described previously (37) (38) (39) . Mutagenesis was then performed according to the manufacturer's instructions using a selection primer 5'-GAG AGT GCA CGA TAT CCG GTG TG-3' that mutates a unique NdeI site in the vector to an EcoRV restriction site. Oligonucleotides bearing mismatched bases at the residues to be mutated (underlined) were synthesized by ACGT Corp. (Toronto, Canada).
They are as follows: T1082A (5'-C TCC AAG GAG CTC GAC GCA GTG GAC TCC-3'), D1084N (5'-CTG GAC ACA GTG AAT TCC ATG ATC CCG-3'), D1084A (5'-CTG GAC ACA GTG AAA TCG ATG ATC CCG-3'), D1084E (5'-CTG GAC ACA GTG GAC TCG ATG 6   ATC CCG-3'), D1084V (5'-CTG GAC ACA GTG GTA TCG ATG ATC CCG-3'), S1085A (5'-CTG GAC ACA GTC GAC GCC ATG ATC CCG G -3'), K1092M (5'-C CCG GAG GTC ATC   ATG ATG TTC ATG GGC-3'), K1092A (5'-C CCG GAG GTC ATC GCG ATG TTC ATG GGC-3'), K1092E (5'-C CCG GAG GTC ATC GAG ATG TTC ATG GGC-3'), K1092R (5'-C CCG GAG GTC ATC AGG ATG TTC ATG GGC-3'), S1097A (5'-G ATG TTC ATG GGC GCC CTG TTC AAC-3'), N1100A (5'-TTC ATG GGC TCG CTC TTC GCC GTC ATT GGT G-3'), N1100S (5'-TTC ATG GGC TCG CTC TTC AGT GTC ATT GGT G-3').
After confirming all mutations by DNA Thermo Sequenase Cy5.5 and Cy5.0 dye terminator cycle sequencing (Amersham Biosciences) according to the manufacturer's instructions, DNA fragments containing the desired mutations were transferred into pCEBV7-MRP1. After reconstructing the mutations into the full-length clones, the integrity of the entire mutated inserts and cloning sites was verified by DNA sequencing (ACGT Corp., Toronto, Canada).
Mutation D1084R was generated using the Quikchange TM Site-Directed Mutagenesis kit (STRATAGENE, La Jolla, CA). Templates were prepared as described previously (44) .
Mutagenesis was then performed according to the manufacturer's instructions. Oligonucleotide bearing mismatched bases at the residues to be mutated (underlined) was synthesized by ACGT Corp. (Toronto, Canada). It is as follow: D1084R (5'-CTG GAC ACA GTG CGG TCC ATG ATC CCG-3'). After confirming the mutation by DNA sequencing (ACGT Corp., Toronto, Canada). DNA fragments containing the desired mutations were transferred into pcDNA3.1-
MRP1.
Cell lines and Tissue Culture-Stable transfection of HEK293 cells with the pCEBV7 vector containing the wild type and mutant MRP1 cDNAs has been described previously (13,37- by guest on July 15, 2017 http://www.jbc.org/ Downloaded from 39). Briefly, HEK293 cells were transfected with pCEBV7 vectors containing mutant MRP1 using Fugene6 (Roche Molecular Biochemicals) according to the manufacturer's instructions.
After ~48 h, the transfected cells were supplemented with fresh medium containing 100 μg/ml hygromycin B. Approximately 3 weeks after transfection, the hygromycin B-resistant cells were cloned by limiting dilution and the resulting cell lines were tested for high level expression of the mutant proteins.
Confocal Microscopy-Confocal microscopy was carried out as described previously (37) (38) (39) . Briefly, ~5x10 5 stably-transfected HEK293 cells were seeded in each well of a 6-well tissue culture dish on coverslips. When the cells had grown to confluence, they were washed once in PBS and then fixed with 2% paraformaldehyde in PBS, followed by permeabilization using digitonin (0.25 mg/ml in PBS). MRP1 proteins were detected with the monoclonal antibody MRPm6. Antibody binding was detected with Alexa Fluor 488 anti-mouse IgG (H+L) (Fab') 2 fragment. Nuclei were stained with propidium iodide. Localization of MRP1 in the transfected cells was determined using a Meridian Insight confocal microscope (filter, 620/40 nm for propidium iodide; 530/30 nm for Fluor 488).
Determination of Protein Levels in Transfected Cells-Plasma membrane vesicles were
prepared by centrifugation through sucrose, as described previously (13, 16) . After determination of protein levels by Bradford assay (Bio-Rad), total membrane protein (0.5, 1.0, and 1.25 µg) from transfectants expressing wild type MRP1 and various mutant proteins were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 7.5% gel.
Proteins were subsequently transferred to Immobilon-P polyvinylidene difluoride membranes Recombinant bacmids and baculoviruses were generated as described previously (45) .
The conditions used for viral infection were also similar to those described previously (45) .
Plasma membrane vesicles were prepared and the expression levels of wild type and mutant protein in infected cells were determined, as described previously (13, 16 gradient gel by SDS-PAGE. The gel was then dried, and exposed to film for 2-hr at room temperature.
Orthovanadate-induced trapping of 8-azido-[α 32 P]ATP by MRP1 was determined as described previously (45) . Briefly, membrane proteins (20 µg of total proteins) were incubated in transport buffer (10 µl) containing 5 mM MgCl 2 , 1 mM sodium orthovanadate, and 8-azido-[α ice-cold stop buffer, and the membranes were centrifuged at 14,000 rpm for 15 min at 4 °C. The pellets were washed again and resuspended in 20 µl of stop buffer. The samples were transferred to a 96-well plate and UV-irradiated. Proteins were analyzed on a 5-15% gradient gel by SDS-PAGE. The gel was then dried, and exposed to film for 6-hr at room temperature.
Chemosensitivity Testing-Drug resistance was determined using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as described previously (10, 11, 13) . Briefly, cells were seeded at 7x10 3 cells/well in 100 μl of culture medium in 96-well tissue culture plate. The following day, various concentrations of drug diluted in culture medium were added to cells (100 μl/well). After incubation for an additional 72 h, 100 μl of medium was removed from each well and the MTT reagent (25 μl/well, 2 mg/ml) (Sigma) was added. After 3 h, the formazan was solubilized by mixing with HCl/isopropanol (1:24) (100 μl/well). Color density was determined using the ELX 800 UV spectrophotometer (Filter4, 570nm). Mean To determine whether these mutations influenced trafficking of the protein, we compared the subcellular localization of wild type and mutant MRP1 by confocal microscopy. As shown in Figure 2B , the subcellular distribution of the mutated proteins assessed by immunoreactivity with the MRP1 specific mAb MRPm6 was indistinguishable from that of cells expressing wild type protein. In all cases, strong plasma membrane staining was observed and no differences in membrane distribution were detected between mutant and wild-type proteins.
Transport of [ 3 H]LTC 4 and [

H]E 2 17βG by wild type and mutant MRP1-To determine
whether any of the TM14 mutations altered the efficiency with which the protein transported LTC 4 and E 2 17βG, we examined ATP-dependent uptake of these compounds by membrane vesicles prepared from HEK transfectants expressing each of the mutant proteins (Fig. 3 ). The levels of LTC 4 uptake by vesicles prepared from HEK transfectants expressing either wild type MRP1 or mutations T1082A, S1085A, K1092M, S1097A, and N1100A were proportional to the relative expression levels of the wild type and mutant proteins. The only mutation that affected with Ala also decreased transport efficiency by 30 to 40%. Thus mutations S1097A and N1100A only affected transport of the estrogen conjugate, whereas mutation D1084N decreased the ability of MRP1 to transport both LTC 4 and E 2 17βG.
Resistance profiles of wild type and mutant human proteins-The drug resistance profiles of transfectants expressing mutant proteins were determined using MTT assays. The results are presented as relative drug resistance factors in Table 1 . Mutations T1082A, S1085A, and N1100A had no significant effect on drug resistance, but conversion of one polar residue, Ser H]GSH by wild type and mutant MRP1-The studies described above indicated that mutations S1097A and D1084N affected the ability of MRP1 to confer drug resistance and to transport conjugated organic anions, while the K1092M mutation influenced only the drug resistance profile of MRP1. One major distinction between MRP1-mediated transport of the conjugated substrates, LTC 4 and E 2 17βG, and drugs such as vincristine and VP-16, is a requirement for GSH, which may be co-transported with the unmodified drug (48, 49) .
Previously, we have reported that MRP1 exhibits low levels of ATP-dependent GSH transport that can be stimulated by compounds such as verapamil (50) . Consequently, we examined the effects of TM14 mutations on verapamil-stimulated GSH transport to determine whether those that affected drug resistance also influenced transport of GSH (Fig. 4) . As observed when examining LTC 4 transport, only replacement of Asp 1084 by Asn influenced the ability of MRP1 to transport GSH, and this mutation essentially eliminated transport activity. Other mutations, including mutations S1097A and K1092M that altered the drug resistance profile of MRP1, had no effect. These findings suggest that the effects of mutations S1097A and K1092M on MRP1-mediated drug resistance appear to be due primarily to changes in the ability to interact with the drug substrate rather than GSH. MRP1-Since mutation D1084N affected the ability of the protein to transport both LTC 4 and E 2 17βG while mutations S1097A and N1100A selectively decreased the transport of only E 2 17βG, we compared their effect on the kinetic parameters of transport of both substrates (Fig.   5 ). For E 2 17βG transport, the normalized V max values for mutations D1084N, S1097A and N1100A were lower than that for wild type MRP1 (3207 pmol/mg/min for wild type MRP1, versus 151, 2279, and 1852 pmol/mg/min for mutations D1084N, S1097A and N1100A, respectively) ( Fig. 5A and Table 2 ). The apparent K m value for mutation N1100A (1.9 μM) was comparable with that of the wild type protein (1.6 μM). However, substitution of Asp D1084N, S1097A and N1100A all decreased the conjugated estrogen transport, the three mutations had different effects on the apparent K m values for E 2 17βG uptake.
For LTC 4 were essentially identical (146, 141, and 138 nM for wild type MRP1 and mutations S1097A and N1100A, respectively) and the normalized V max values for mutations S1097A and N1100A were also very similar with that of wild type MRP1 (223, 208, and 242 pmol/mg/min for mutations S1097A, N1100A, and wild type MRP1, respectively) ( Figure 6B ). In addition, we examined photolabeling in the presence of ATP and vanadate to determine whether the mutant was altered in its ability to form a low-affinity transition state. As we have shown previously, the presence of ATP significantly decreased the photolabeling of the wild type protein and this effect was further enhanced in the presence of vanadate (46) . In contrast, the photolabeling of mutant MRP1 were only slightly lower than those the wild type half molecules (Fig. 7A) . The ATP-dependent LTC 4 uptake by reconstituted mutant and wild type proteins was then determined by transport assays (Fig. 7B (Fig. 7C) , consistent with previous studies (46) . However, the labeling of both the NH 2 -and the COOH-proximal halves of mutant MRP1 D1084N with LTC 4 was unaffected by ATP (Fig. 7C) with Ala selectively decreased the transport of E 2 17βG. This residue is not conserved between the human and rodent proteins. In both rat and mouse MRP1, the comparable residue is Ser. We have shown previously that both rodent proteins transport E 2 17βG far less efficiently than human MRP1 and that non-conserved amino acid residues located within a region between amino acids 959 to 1197 of human MRP1 are partially responsible for the higher efficiency with which the human protein transports E 2 17βG (51,52). To date only one such residue, Glu 1089 , has been identified (37) . Consequently, we also mutated Asn 1100 to Ser, as it is in the rodent proteins.
These mutations were then stably expressed in HEK293 cells. The expression levels of these mutant proteins in stably transfected HEK293 cells were similar to that of wild type MRP1 (Fig.   8A ).
The effects of all of the mutations on the ability of MRP1 to transport LTC 4 and E 2 17βG are shown in Fig. 8B and 8C . Mutations K1092A, K1092R and K1092E had no effect on transport of either LTC 4 
with Ala, Arg and Val dramatically decreased the ability of MRP1 to transport both LTC 4 and E 2 17βG while conversion to Glu also resulted in an approximate 50% decrease in transport of both substrates. We also examined the ability of the mutants D1084E and D1084R to bind [ 3 H]LTC 4 by photolabeling studies. As shown in Figure   8E , the relative normalized densitometry values of photolabeling of D1084E and D1084R with 
Effects of mutations on drug resistance profile of MRP1-The capacity of these mutant
proteins to confer drug resistance was also examined by MTT assay (Table 3) . Mutation N1100S had no effect on the drug profile of MRP1. The mutation K1092R also showed the same phenotype as wild type MRP1, while mutations K1092A and K1092E, like K1092M, increased the ability of MRP1 to confer resistance to vincristine and doxorubicin but not to VP-16.
Substitution of Asp 1084
with Ala and Val, as observed with mutation D1084N, significantly reduced resistance to vincristine, VP-16, and doxorubicin. Interestingly, replacement of Asp resistance to vincristine and doxorubicin, but unaltered ability to confer VP-16 resistance, (Table   3 ). These findings suggest that size together with charge in the side chain of residue at position 1084, and positive charge in the side chain of residue at position 1092 are important for determining the drug resistance profile of MRP1.
DISCUSSION
Unlike MRP1, orthologs from mouse, rat and cow fail to confer anthracycline resistance (13, 52, 53) . We have shown that this is due at least in part to the presence of Glu position 1089 in MRP1 rather than Gln, which is found at the comparable locations in the mouse and rat proteins.
Conservative mutation of Glu 1089 of MRP1 to Asp has little effect on substrate specificity.
However, elimination of the carboxylate side chain by mutation to Gln completely eliminates athracycline resistance (37) . Glu 1089 is predicted to be in the middle of TM14 of MRP1. The topologically comparable TM helix in P-gp, due to the five additional NH 2 -proximal TMs in MRP1, is TM9. Amino acids in this helix have also been demonstrated recently to contribute to the specificity of substrate binding of hamster and human P-gp (42, 43) . For example, Ala 841 , predicted to be the middle of TM9 of P-gp, appears to be involved in the binding of rhodamine dyes (42) . In addition, we have shown that certain residues with side chain hydrogen bonding potential, clustered in the cytoplasmic half of TM17 of MRP1 contribute to defining substrate specificity (38) (39) (40) . These studies also revealed a highly specific functional interaction between with Glu resulted in a mutant protein which retained approximately 50% of the wild type protein's ability to transport LTC 4 and E 2 17βG, and to confer vincristine and doxorubicin resistance, while having no effect on VP-16 resistance.
Thus reducing the length of the side chain by only a single methylene group had a readily detectable effect on transport of two structurally unrelated conjugated anions and on the ability to confer resistance to two structurally unrelated cationic drugs. This result combined with the effect of mutations that eliminate the negative charge of the side chain suggested that the presence and position of the carboxyl group may be critical for a common step in the transport process, rather than interaction with specific substrates.
In addition, we also demonstrated the important role of Lys doxorubicin, but had no effect on resistance to the electroneutral drug VP-16, or the transport of organic anionic conjugates. On the other hand, mutations S1097A, N1100A and N1100S reduced E 2 17βG but not LTC 4 or GSH transport activity. Mutation S1097A also reduced resistance to all three classes of drugs tested. Examination of a helical wheel projection of TM14 of MRP1 indicates that it is highly amphipathic with all polar residues, except for Asp 1084 , which influenced the overall activity of MRP1, located on one face of the helix (Fig. 9) . resistance to all three drugs tested. A large body of evidence has suggested that unmodified drugs are transported by MRP1 via a co-transport mechanism with reduced glutathione (48, 49) .
However, in the present study, we did not observed any effect of mutation S1097A on verapamil-stimulated GSH transport by MRP1. These findings suggest that Ser 1097 might be involved in the interaction of MRP1 with the drug substrate rather than GSH. In addition, in contrast to the effect of mutation S1097A on E 2 17βG transport, mutation N1100A which only affected the transport of E 2 17βG, decreased the V max without significantly affecting K m , suggesting that the mutation affects a step in the transport process subsequent to initial binding of this substrate. Asn 1100 is not conserved among the human and rodent proteins. In rat and mouse MRP1, the comparable residue is Ser. As indicated above, although both mouse and rat MRP1 transport LTC 4 with efficiencies similar to that of the human protein, they are relatively poor transporters of E 2 17βG (13, 52) . We recently showed that conversion of Ser 1101 in TM14 of rat MRP1 to Asn, as it is in human MRP1, increased the ability of rat protein to transport the glucuronidated estrogen (52) . Consistent with these results, we found that replacement of Asn which is predicted to be in TM6. Mutations of Asp than the wild type protein, suggesting that the affinity for both substrates was actually increased.
However, we did not observe a significant increase in photolabeling of the mutant protein by LTC 4 . This may be attributable to the fact that the initial photolabeling experiments, in contrast to transport assays were carried out in the absence of ATP. We have shown previously that in the presence of ATP, LTC 4 photolabeling of the wild type protein is decreased and that this decrease requires that NBD2 be competent to trap ADP (46) . Consistent with this suggestion, we found that LTC 4 binding by the D1084N mutation did not decrease in the presence of ATP even with the addition of vanadate. This finding together with the effect of mutation D1084N on the overall activity of MRP1 raised the interesting possibility that the mutation might affect the binding and/or hydrolysis of ATP, so that substrate could not be translocated and/or released from the mutant protein. We detected no change in binding of ATP at 4 ºC by either NBD of the mutant protein, but the conformational change that results in decreased LTC 4 binding does not occur at this temperature. At 37 ºC, the D1084N mutation drastically decreased trapping of 8-azido-ADP at NBD2 when photolabeling was carried out in the absence or presence of vanadate. These findings indicate that the mutation D1084N decreased the ability of NBD2 to hydrolyse ATP. In recent studies we have determined that ATP binding by NBD2, rather than hydrolysis, is sufficient to result in a conformational change that decreases the affinity of MRP1 for LTC 4 and that this persists while NBD2 is occupied by either ATP or ADP (58) . Consequently, the primary effect of the mutation may be at the level of ATP binding by NBD2, a process that we and others have shown to be strongly stimulated by ATP binding to NBD1 (44, 59) . The kinetic parameters of LTC 4 and E 2 17βG uptake were determined as described in the legend to Figure 5 . The resistance of HEK293 cells transfected with expression vectors encoding wild type and mutant MRP1 relative to that of cells transfected with empty vector were determined as described in Table 1 1110  1098  851  1001  1074  1075  949  938  1002  1150  1122   TVDSMIPEVIKMFMGSLFNVI  TVDSMIPQVIKMFMGSLFSVI   TVDDTLPQSLRSWITCFLGII  VVDEVLAPVILMLLNSFFNAI  HLDDLLPLTFLDFIQTLLQVV  EVDVRLPFQAEMFIQNVILVF  TVDVDIPDKLRSLLMYAFGLL  CADDSLPFILNILLANAAGLL  QLDQLLPIFSEQFLVLSLMVI  ELDVRLPFHAENFLQQFFMVV  ILDDLLPLTIFDFIQLLLIVI  TIDQHIPSTLECLSRSTLLCV 
